Hybrid acute leukemia: therapeutical implications of immunological phenotyping

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute leukemia, particularly Philadelphia chromosome-positive (Ph1+) cases, presents complex diagnostic and therapeutic challenges.
• Biphenotypic acute leukemia, exhibiting characteristics of both myeloid and lymphoid lineages, requires precise characterization for effective treatment.

Observation:

• Longitudinal immunophenotyping of blood and bone marrow cells was performed on a patient with Ph1+ acute leukemia during chemotherapy.
• Initially, blast cells displayed distinct phenotypes: one expressing CD10, CD13, and CD33 but lacking CD20; the other lacking CD10 and CD33.
• During acute myeloid leukemia (AML) induction therapy, the cell phenotype shifted towards a CD10+, CD20+ acute lymphoblastic leukemia (ALL)-like profile.

Findings:

• Concomitant immunophenotyping and cell cycle analysis indicated a proliferation advantage in the more lymphoid-appearing malignant cells.
• Therapy guided by these phenotypic shifts led to improved bone marrow function.

Implications:

• These findings suggest that the phenotype of hybrid malignant cells in acute leukemia can be modulated by treatment.
• Longitudinal immunophenotyping is crucial for optimizing therapeutic strategies in biphenotypic and hybrid acute leukemias.
• The study highlights the potential for lineage-associated phenotypic changes to influence treatment response and patient outcomes.